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Introduction
Consumption of red meat is positively 
correlated with some human cancers, and 
cooking meat produces heterocyclic amines 
(HCAs) and polycyclic aromatic hydro­
carbons (PAHs) (Sinha et al. 2005). The HCA 
2­amino­1­methyl­6­phenylimidazo[4,5­b]
pyridine (PhIP) is bioavailable to humans who 
consume cooked meat (ingesting 0.1–15 μg 
PhIP per day) (Felton et al. 2002). PhIP is 
a rodent carcinogen (Sugimura 1997), 
inducing cancer in the prostate, colon, 
and mammary gland of rats (Crofts et al. 
1997; Ito et al. 1991). The activation of 
PhIP to DNA­damaging species occurs via 
N­hydroxylation catalyzed by cytochromes 
P450 (CYP) 1A1 and 1A2 (Crofts et al. 
1997; Zhao et al. 1994), thereby forming 
promutagenic adducts at C8 of guanine and 
resulting in GC:TA transversions and dele­
tions (Boyce et al. 2014; Lynch et al. 1998). 
Benzo[a]pyrene (BaP) is a carcinogen that 
is generated by incomplete combustion of 
organic substances, leading to the contami­
nation of numerous foodstuffs (Lijinski and 
Shubik 1964). BaP is metabolized by enzymes 
from the CYP1A family to epoxide deriva­
tives that form DNA adducts and result in 
mutation and tumors [International Agency 
for Research on Cancer (IARC) 2010]. 
Through the consumption of contaminated 
food, the average human daily exposure to 
BaP is estimated to be 1–500 ng (IARC 
2010). Experimental studies suggest a positive 
link between exposure to BaP and cancer in 
animals and in humans (Sinha et al. 2005).
Published assessment of genotoxic 
carcinogens, particularly dietary carcinogens, 
in mixtures is limited. Current approaches 
to mixtures risk assessment include whole­
mixture– and component­based methods 
[Agency for Toxic Substances and Disease 
Registry (ATSDR) 2004; U.S. Environmental 
Protection Agency (EPA) 2000]; whole­
mixture approaches are preferred because 
they account for unidentified components 
and interactions between chemicals . 
However, the complexity and variability of 
mixtures makes this approach difficult, and 
component­based methods such as dose or 
response additivity are often used (Boobis 
et al. 2011; COT 2002; Lutz et al. 2005). 
Synergistic effects from interactions between 
PAHs on DNA adduct levels have been 
reported (Staal et al. 2007; Tarantini et al. 
2009, 2011), and prolonged activation of 
DNA damage signaling suggestive of persis­
tent DNA damage by mixtures of PAHs has 
been observed (Jarvis et al. 2013; Mattsson 
et al. 2009; Niziolek­Kierecka et al. 2012), 
suggesting that the present risk assessment 
strategies may underestimate risk. Contrasting 
studies showing antagonistic or additive effects 
from mixtures of PAHs (Courter et al. 2008; 
Mahadevan et al. 2007; Marston et al. 2001; 
Staal et al. 2008; White 2002) or of hetero­
cyclic aromatic amines (Dumont et al. 2010) 
have been published. To our knowledge, 
there is no information regarding mixtures 
of PAHs with HCAs at concentrations that 
are relevant to human exposure [micromolar 
to subnanomolar concentrations, with the 
highest concentrations in gastrointestinal (GI) 
microenvironments]. Such information is 
important for risk assessment of food­borne 
chemical carcinogens. Thus, our aim was to 
determine the mutagenic response to mixtures 
of BaP and PhIP at concentrations relevant to 
human exposure.
Methods
Materials. RPMI­1640 medium (with 
phenol red, without L­glutamine and histi­
dine), heat­inactivated horse serum (HIHS), 
L­glutamine, penicillin/streptomycin, and 
hygromycin B were obtained from Life 
Technologies (Paisley, UK). All other chemi­
cals were purchased from Sigma­Aldrich 
(Poole, UK).
Cell culture. MCL­5 is a human B 
lymphoblastoid cell line that constitutively 
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Background: Chemical carcinogens such as benzo[a]pyrene (BaP) and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) may contribute to the etiology of human diet-associated 
cancer. Individually, these compounds are genotoxic, but the consequences of exposure to mixtures 
of these chemicals have not been systematically examined.
oBjectives: We determined the mutagenic response to mixtures of BaP and PhIP at concentra-
tions relevant to human exposure (micromolar to subnanomolar).
Methods: Human MCL-5 cells (metabolically competent) were exposed to BaP or PhIP 
 individually or in mixtures. Mutagenicity was assessed at the thymidine kinase (TK) locus, CYP1A 
activity was determined by ethoxyresorufin-O-deethylase (EROD) activity and qRT-PCR, and cell 
cycle was measured by flow cytometry.
results: Mixtures of BaP and PhIP produced dose responses different from those of the individual 
chemicals; we observed remarkably increased mutant frequency (MF) at lower concentrations 
of the mixtures (not mutagenic individually), and decreased MF at higher concentrations of the 
mixtures, than the calculated predicted additive MF of the individual chemicals. EROD activity and 
CYP1A1 mRNA levels were correlated with TK MF, supporting involvement of the CYP1A family 
in mutation. Moreover, a cell cycle G2/M phase block was observed at high-dose combinations, 
consistent with DNA damage sensing and repair.
conclusions: Mixtures of these genotoxic chemicals produced mutation responses that differed 
from those expected for the additive effects of the individual chemicals. The increase in MF for 
certain combinations of chemicals at low concentrations that were not genotoxic for the individual 
chemicals, as well as the nonmonotonic dose response, may be important for understanding the 
mutagenic potential of food and the etiology of diet-associated cancers.
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expresses CYP1A1 (Crespi et al. 1991) 
and stably expresses transfected CYP3A4, 
CYP2E1, CYP1A2, CYP2A6, and micro­
somal epoxide hydrolase (Crespi et al. 1991). 
Thus, this cell line can activate BaP and PhIP 
to DNA­damaging species without the need 
for exogenous activation systems (S9 fraction). 
Moreover, these cells are relevant to the human 
exposure route (the diet) because CYP1A1 is 
expressed in the GI tract (Paine et al. 2006). 
Cells were cultured in RPMI­1640 medium 
supplemented with 10% (v/v) HIHS, 2 mM 
L­glutamine, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 2 mM hist idinol,  and 
200 μg/mL hygromycin B; this medium was 
called R10. Stocks were not cultured beyond 
5 weeks (Johnson et al. 2010).
HAT treatment of cells. To remove back­
ground mutants, MCL­5 cells were cultured 
for 3 days in R10 containing HAT [hypoxan­
thine, aminopterin, thymidine; Hybri­Max™ 
(Sigma­Aldrich, Poole, UK)], which is lethal 
to cells harboring mutations at the TK locus 
(Busby et al. 1994). Subsequently, the cells 
were transferred to media containing HT 
(hypoxanthine, thymidine; Hybri­Max™) for 
24 hr; then, the mutant­depleted cultures 
were maintained for 4 days in normal media 
prior to freezing.
TK forward mutation assay. Mutation 
assays used HAT­treated cells (50 mL at 
4 × 105 cells/mL) with BaP or PhIP or binary 
mixtures to achieve the final concentrations 
outlined in Table 1. Dimethylsulfoxide 
(DMSO; 0.1% vol/vol) and ethyl meth­
anesulfonate (EMS; 10 μg/mL) were the 
negative and positive controls for all experi­
ments, respectively. Mutation data were 
considered acceptable provided that the 
relative total growth (RTG) and mutant 
frequency (MF) for both DMSO and EMS 
controls complied with historical data 
and that RTG additionally complied with 
Organisation for Economic Co­operation and 
Development (OECD) guidelines (data not 
shown) (OECD 1997). Published method­
ology (Clements 2000) was followed, with 
some optimizations. Cells were treated for 
24 hr at 37°C and 5% CO2 in RPMI­1640 
containing all supplements but with reduced 
serum [5% (v/v) HIHS]. After treatment, 
the cellular concentration was adjusted to 
4 × 105 cells/mL, and the cells were subcul­
tured daily for 2 additional days to determine 
the relative suspension growth (RSG). On the 
third day, cells were plated (10 cells/well in 
2 × 96­well plates) for cloning efficiency (CE) 
and 20,000 cells/well in 3 × 96­well plates in 
trifluoro thymidine (TFT; 4 μg/mL) to deter­
mine thymidine kinase (TK) MF. Plates were 
incubated for 21 days to determine MF. RTG 
was calculated to estimate cytotoxicity, and 
MF was expressed as mutants/106 viable cells 
(Clements 2000).
Ethoxyresorufin-O-deethylase (EROD). 
Ethoxyresorufin­O­deethylase (EROD, an 
indicator of CYP1A activity) was measured 
as the conversion of 7­ethoxyresorufin 
(7­ER) to resorufin. Cell suspensions 
(10 mL at 4 × 105 cells/mL) were treated 
with selected concentrations of BaP, PhIP, 
or combinations of BaP and PhIP for 24 hr.
Then, 3 × 106 cells were collected for EROD 
activity analysis by centrifugation [200 × g, 
5 min, room temperature (RT)], washed 
once in phenol red–free/serum­free RPMI­
1640 media (R0) and resuspended in 1 mL 
R0 media in 24­well plates. We added (1 
μL DMSO to give a final concentration of 
8 μM) 7­ER to the wells, and the cells were 
incubated for 90 min at 37°C. Fluorescence 
was measured at λexcitation = 560 nm 
and λemission = 590 nm every 10 min 
(POLARstar Galaxy Microplate Reader, 
BMG Lab Technologies). Activity was 
expressed as picomoles of resorufin produced 
per minute per 106 cells using a resorufin 
standard curve.
Protein determination. Cells (3 × 106) 
collected by centrifugation (450 × g, 5 min, 
RT) were treated with RIPA buffer (Sigma) 
containing Halt protease inhibitor cocktail (Life 
Technologies) for 30 min on ice. The lysate was 
clarified by centrifugation (8,000 × g, 10 min, 
4°C), and the supernatant was collected and 
stored at –20°C. Lysate protein was deter­
mined using the bicinchoninic acid (BCA) 
assay (Pierce, Thermo Scientific) following the 
manufacturer’s instructions.
Immunoblotting. Protein samples (20 μg) 
were mixed with 5× loading buffer containing 
β­mercaptoethanol, and the volume was 
adjusted to 25 μL. Samples were boiled 
(95°C, 5 min), centrifuged (10,000 × g, 
5 min), and loaded onto a 10% sodium 
dodecyl sulfate (SDS)­polyacrylamide gel 
and electrophoresed (100 V, 1.5 hr). Proteins 
were transferred to nitrocellulose membrane 
(150 V, 400 mA, 1.5 hr), and Ponceau 
S stain was used to confirm the transfer. 
The membrane was blocked (PBS­T 0.1% 
Tween 20, 5% milk powder) and then incu­
bated with antibodies for MSH2 or MSH6 
(Abcam, 1:1,000 dilution, 4°C overnight). 
The membrane was incubated with a horse­
radish peroxidase (HRP)–coupled goat anti­
rabbit or goat anti­mouse secondary antibody 
(Abcam, 1:10,000 dilution) for 1 hr at room 
temperature. Protein bands were detected 
using Luminata Forte Western HRP substrate 
(Merck­Millipore) and visualized using the 
ChemiDoc XRS+ Molecular Imager System 
(BIO­RAD, San Francisco, CA, USA). 
Blots were probed for β­actin as a loading 
control; the primary antibody (1:200; Sigma) 
was incubated for 1 hr; then, the secondary 
antibody (goat anti­mouse, 1:10,000; Abcam) 
was incubated for 1 hr.
RNA extraction and quantitative 
RT-PCR (qRT-PCR). Following treatment 
with selected concentrations of mixtures of 
BaP and PhIP, cells (3 × 106) were collected 
by centrifugation (200 × g, 5 min, RT). The 
pellets were resuspended in 0.5 mL TRIzol 
(Invitrogen, Paisley, UK) for RNA extraction, 
quantified (Implen nanophotometer; GmbH, 
Munchen, Germany), and the A260/280 
and A260/230 ratios were used to assess 
RNA quality. To synthesize cDNA, 1 μL of 
random primers was added to 500 ng of RNA 
(adjusted to a final volume of 15 μL with 
RNase/DNase–free dH2O) and incubated 
for 5 min at 65°C. The mixture was placed 
on ice before adding 0.2 mM dNTPs, 5 μL 
5× first­strand buffer, 2 μL 0.1 mM DTT, 
and 0.5 μL Superscript II reverse transcriptase 
Table  1.  Relative total  growth (RTG) and 
 background- corrected mutation frequency 
(MF/106 viable cells) at the thymidine kinase (TK) 
locus following treatment with different concen-
trations of BaP and PhIP alone or in selected 
combinations.
Treatment and 
concentration (M) RTGa TK MFb
BaP 0.1 ± 1.3
10–10 98.7 ± 0.7 0.1 ± 1.5
10–9 95.1 ± 3.8 0.1 ± 1.8
10–8 87.6 ± 5.9 1.3 ± 1.2
10–7 85.6 ± 6.1 30.1 ± 4.3**
2.5 × 10–7 85.6 ± 7.9 44.5 ± 4.7***
7.5 × 10–7 74.1 ± 1.4 46.5 ± 6.9***
10–6 74.2 ± 4.0 54.4 ± 3.6***
2.5 × 10–6 85.9 ± 6.5 61.4 ± 8.5***
7.5 × 10–6 64.4 ± 0.4 76.9 ± 10.5***
10–5 56.4 ± 7.7 0.1 ± 1.3
PhIP
10–9 98.0 ± 3.9 0.7 ± 0.4
10–8 113.2 ± 3.2 0.1 ± 1.3
10–7 112.6 ± 6.8 5.6 ± 2.4
10–6 114.2 ± 5.9 2.1 ± 1.6
10–5 103.9 ± 2.9 5.1 ± 1.5
5 × 10–5 89.2 ± 4.9 7.0 ± 1.6**
7.5 × 10–5 78.6 ± 4.7 8.8 ± 1.2*
10–4 83.0 ± 5.4 7.9 ± 2.4**
BaP + PhIP
10–9 + 10–9 109.8 ± 8.6 2.47 ± 2.13
10–7 + 10–6 95.2 ± 7.8 43.6 ± 11.38***
10–7 + 5 × 10–5 113.2 ± 12.2 0.1 ± 4.72
10–7 + 10–4 89.4 ± 9.4 4.28 ± 2.81
2.5 × 10–7 + 10–6 117.5 ± 8.8 56.81 ± 10.68***
10–6 + 10–6 118.2 ± 1.2 39.71 ± 4.56*
10–6 + 5 × 10–5 60.1 ± 8.2 17.5 ± 4.17*
10–6 + 10–4 113.7 ± 13.3 2.93 ± 3.14
10–5 + 10–6 48.3 ± 3.4 41.1 ± 5.22***
10–5 + 5 × 10–5 100.9 ± 7.4 16.85 ± 5.28*
10–5 + 10–4 81.6 ± 12.5 7.92 ± 2.49
DMSO negative control average range, 4.9–18.6 MF/106 
viable cells; EMS positive control average range, 
74.6–125.5 MF/106 viable cells. Historical controls: TK: 
DMSO, 13.3 ± 9.4 MF/106 viable cells ± standard devia-
tion; EMS (positive control), 99.4 ± 40.4 MF/106 viable 
cells  ±  standard deviation. aRTG values are percent 
means ± standard error of the mean (SEM), n = 3–12. 
bData are presented as background-corrected 
means ± standard error of the mean (SEM), n = 3–12. 
Significance compared with the DMSO control calcu-
lated using one-way analysis of variance (ANOVA) with 
Dunnett’s post-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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(Superscript II kit, Life Technologies). 
Samples were run on a thermocycler (25°C, 
10 min; 42°C, 90 min; 70°C, 15 min). 
CYP1A1 cDNA was amplified by qRT­PCR. 
As an internal control, endogenous glyc­
eraldehyde­3­phosphate dehydrogenase 
(GAPDH) cDNA from the same cellular 
extracts was also amplified. cDNA was ampli­
fied using a Taqman Fast 2× Universal PCR 
master mix, No AmpErase UNG kit (Life 
Technologies); all samples were analyzed in 
triplicate. qRT­PCR data were analyzed using 
the ABI 7500 Sequence Detection System 
(Life Technologies) and the comparative CT 
(threshold cycle) method (ΔCT method) 
(Livak and Schmittgen 2001). Calibration 
was based on the expression of GAPDH.
Flow cytometry analysis of cell cycle distri-
bution. Cell cycle stage was determined using 
flow cytometry. MCL­5 cells were resus­
pended in 1 mL 70% ethanol (in phosphate­
buffered saline; PBS) at –20°C. Cells were 
collected by centrifugation (450 × g, 10 min, 
4°C), washed once in PBS, resuspended in 
200 μL PBS containing propidium iodide 
(5 μg/mL) and RNase A (0.1 mg/mL), 
incubated (37°C, 30 min), and examined 
by flow cytometry (Fortessa II, Beckman 
Coulter); cell cycle distribution was deter­
mined using FloJo software (Tree Star Inc., 
Ashland, OR, USA).
Statistical analysis of mutation data to 
determine synergy/antagonism. Median effect 
plot and combination index (CI). Data were 
analyzed using the method of Chou (2006) 
with background­corrected MF. Median 
effect plots of log(dose) versus log(fa/fu), 
where fa is the fraction affected (MF/106 
viable cells) and fu is 106 – fa, were drawn for 
individual chemicals to obtain the slope (m), 
the median effect dose (Dm, calculated as the 
antilog of the x intercept when y = 0), and 
the Pearson correlation coefficient (r), which 
signify the shape of the dose–effect curve, 
the potency (IC50), and the conformity of 
the data to the mass action law, respectively. 
From these plots, doses of the individual 
chemicals required to produce the mixture 
effect were calculated using Equation 1:
 Dx = Dm[fa(mix)/1 – fa(mix)]1/m. [1]
The CI was calculated using Equation 2:
 CI = D1/Dx1 + D2/Dx2, [2]
where D1 and D2 are the concentrations of 
the individual chemicals used in the mixture, 
and subscripts 1 and 2 refer to the two 
components of the mixture.
For the CI calculation, the value of D was 
also calculated using Equation 1. Whereas 
D represents the dose of individual chemical 
used in the mixture, Chou (2006) states that 
“dose and the effect are interchangeable since 
the dose (D) for any given effect (fa) can be 
determined if the values for Dm and m are 
known.” Because Dm and m were obtained 
from the median effect plot, from which the 
Dx values were also derived, it was noted 
that calculating D based on these values gave 
modified doses; thus, we have adjusted D to 
reflect the median effect plot.
Synergism and antagonism are deter­
mined f rom CI and are  subdiv ided 
into nearly additive (NDAd, 0.9–1.1), 
moderate synergism/antagonism (mS, 
0.7–0.90/mA, 1.1–1.45), synergism/antago­
nism (S, 0.3–0.7/A, 1.45–3.3), and strong 
synergism/antagonism (sS, < 0.3/sA, > 3.3) 
(Chou 2006).
Interaction factor (IF). Data were also 
analysed using the interaction factor (IF), which 
was calculated with background­corrected MF 
following the method described by Danesi 
et al. (2012). The IFs were calculated using 
Equation 3:
 IF = G1G2 – G1 – G2 + C, [3]
where G1G2 is the MF obtained for treatment 
with the mixture, G1 and G2 are the MF 
obtained for treatment with the individual 
chemicals, and C is the MF obtained for the 
control. A negative IF denotes antagonism, a 
positive IF denotes synergism, and a zero IF 
denotes additivity.
The standard error of the mean (SEM) of 
the IF was calculated as described by Danesi 
et al. (2012) using Equation 4:
SEM =  
√(SEMG1G2)2 + (SEMG1)2 + (SEMG2)2 + C, 
 [4]
where SEMG1G2 is the SEM for the mixture.
Independent action (IA). Concentration–
response relationships for mixtures of 
compounds  are  predic ted  based on 
 concentration–response data for individual 
mixture components, assuming additivity 
(Rajapakse et al. 2001). Synergism and antago­
nism can be defined as deviations from the 
expected effects, with synergistic mixtures 
showing higher, and antagonistic mixtures 
lower, responses than predicted. When the 
predictions are met, the combined response 
is additive (Berenbaum 1989). Independent 
action (IA) describes situations where 
compounds act on different subsystems, 
possibly involving different sites and modes 
of action (Rajapakse et al. 2001). Because the 
chemicals used in this study have different 
mechanisms of action [both chemicals are 
activated by CYP1A1, and PhIP is addition­
ally activated by CYP1A2 (Crofts et al. 1997; 
IARC 2010; Zhao et al. 1994), and because 
DNA damage from BaP is a result of ROS and 
epoxides whereas PhIP induces DNA damage 
via a nitrenium ion (IARC 2010; Singh et al. 
2010)], IA was also used to determine the 
expected response.
IA can be calculated using Equation 5 as 
described by Berenbaum (1989):
E(da, db) = E(da) + E(db) – E(da)E(db), [5]
where E(da, db) is the fractional effect of the 
mixture, and E(da) and E(db) represent the 
fractional effects of the individual chemicals. 
In this equation, fractional effect E is used 
as a substitute for the probability of occur­
rence of an event and fractional lack of 
effect (Berenbaum 1989). When applying 
this model, a maximal effect must be defined 
(Rajapakse et al. 2001). In the present study, 
the fractional effect E was the MF, which was 
expressed as the number of mutants per 106 
viable cells; thus, we assumed that the unit of 
assessment was the cell and that the maximal 
effect was 106 mutants per 106 cells.
IA was calculated using Equation 6, based 
on the equation employed by Abendroth 
et al. (2011):
 IA = E1 + E2 – (E1E2/106), [6]
where IA is the predicted mixture percent 
response assuming additivity, E1 is the 
observed percent response for chemical 1 
alone, and E2 is the observed percent response 
for chemical 2 alone.
Statistical analysis. Statistical significance 
was determined using a one­way analysis of 
variance (ANOVA) with Dunnett’s post­test. 
Statistical significance was defined as p < 0.05.
Results
TK forward mutation assay for individual 
chemicals. The concentrations of BaP and 
PhIP that were used were chosen to cover 
a range of values from typical human 
dietary exposure (< 10–8 M) (IARC 2010; 
Sinha et al. 2005) to high concentra­
tions that induce a high mutant frequency 
(Felton et al. 2002; Yadollahi­Farsani et al. 
1996). BaP produced a statistically signifi­
cant increase in TK MF from 2.5 × 10–7 to 
10–5 M (Figure 1A), whereas treatment of 
cells with PhIP required higher doses than 
those used for BaP (Figure 1B). PhIP has 
been reported to be a poor mammalian cell 
mutagen in in vitro assays (Knize et al. 2002; 
Yadollahi­Farsani et al. 1996), requiring doses 
in the 10–5–10–4 M range, consistent with the 
present study.
Mutant frequency at the TK locus for 
binary mixtures. The observed TK MF 
differed from the expected additive response 
(based on addition of the MF of individual 
chemicals and on the IA model). In general, 
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MF was increased for low­concentration 
mixtures and decreased for high­concentra­
tion mixtures relative to the expected response 
if the MF for individual chemicals was 
additive. For example, a remarkable statisti­
cally significant increase in MF was observed 
for the combination of 10–7 M BaP and 
10–6 M PhIP (TK MF = 43.6 ± 7.0), whereas 
these concentrations of BaP and PhIP alone 
did not significantly increase the MF (TK 
MF = 1.3 ± 1.2 and 5.6 ± 2.4, respectively) 
(Figure 1C; Table 1). In contrast, the MF 
observed for 10–5 M BaP combined with 
10–4 M PhIP (TK MF = 7.9 ± 2.5) was 
considerably lower than anticipated, given 
that individually, these concentrations 
produced significant increases in MF (TK 
MF = 76.9 ± 10.5 and 7.9 ± 2.4, respec­
tively) (Figure 1C and Table 1). The RTG 
for the different mixtures did not change 
significantly from the RTG observed when 
the same concentrations were tested for the 
chemicals individually, suggesting no signifi­
cant toxicity from the individual or combined 
treatments (Table 1).
Statistical analysis of the binary mixture 
data. Three methods of statistical determina­
tion of interaction were employed to assess 
whether the effects of mixtures of BaP and 
PhIP were additive, synergistic, or antago­
nistic. The median effect equation derived 
from the mass action law principle (Chou 
2006) allows quantitative determination of 
chemical interactions that lead to biological 
responses. This approach has previously been 
employed for mixtures where a maximum 
effect is achievable, (e.g., enzyme inhibition) 
(Chou and Talalay 1984), but has not, to 
our knowledge, been applied to mutation 
data. Here, we define a theoretical maximum 
effect limit for mutation (i.e., 106 mutants 
per 106 cells). This assumption is not achiev­
able in practice because mutation at this 
frequency is incompatible with survival. An 
alternative method is to use the interaction 
factor (IF) (Schlesinger et al. 1992), which 
has recently been applied to genotoxicity data 
in Drosophila (Danesi et al. 2012). Finally, 
response addition based on independent 
action (IA), which represents a situation in 
which compounds act on different subsystems 
that may involve different sites and modes of 
action (Rajapakse et al. 2001), was calculated 
for the mixtures. This method determines 
outcome based on additivity, and synergism 
and antagonism can be defined as deviations 
from the expected effects. The results from all 
three analyses showed a synergistic inter action 
for the combination of BaP 10–7 M and 
PhIP 10–6 M, and the difference between the 
observed and predicted joint effect was statis­
tically significant based on IA. In contrast, six 
combinations of BaP ≥ 10–6 M with doses of 
PhIP ≥ 10–6 M were consistently categorized 
as antagonistic by all three methods, with 
statistically significant differences between the 
observed and predicted joint effects based on 
IA for five of the six combinations (Table 2).
Ethoxyresorufin-O-deethylase (EROD) 
activity. BaP and PhIP must undergo meta­
bolic activation catalyzed by CYP1A to 
become genotoxic. EROD, an indicator of 
Figure 1. Effects of BaP, PhIP, or BaP/PhIP mixtures on mutant frequency (MF) at the TK locus. Background-
corrected MF at the TK locus following a 24-hr treatment with (A) BaP, (B) PhIP, or (C) BaP/PhIP mixtures; in 
(C), open bars represent the predicted MF based on additivity, and solid bars represent the actual MF. The 
green bars represent the measured MF for PhIP alone, the blue bars represent the measured MF for BaP 
alone, and the teal bars represent the measured MF for PhIP/BaP mixtures. DMSO negative control average 
range, 4.9–18.6 MF/106 viable cells; EMS positive control average range, 74.6–125.5 MF/106 viable cells. 
Historical controls: TK: DMSO, 13.3 ± 9.4 MF/106 viable cells ± standard deviation; EMS (positive control), 
99.4 ± 40.4 MF/106 viable cells ± standard deviation; Data are means ± SEM, n = 3–12 independent cultures. 
Significance compared with DMSO control [one-way analysis of variance (ANOVA) with Dunnett’s post-test; *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001].
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Table 2. Analysis of the mutation frequency data at the TK locus for binary mixtures of BaP and PhIP by 
the median effect equation and the combination index theorum (CI), interaction factor (IF), or indepen-
dent action (IA).
BaP + PhIPa fab CIc
Mechanism 
(CI)d IF ± SEMe
Mechanism 
(IF)e
Predicted 
MF with IAf
Mechanism 
(IA)g
10–9 + 10–9 2.47 ± 2.13 0.02 sS 1.64 ± 3.42 NDAd 0.83 NDAd
10–7 + 10–6 43.60 ± 11.38 0.007 sS 40.25 ± 7.61 S 3.35*** S
10–7 + 5 × 10–5 0.10 ± 4.72 3.83 × 106 sA –8.15 ± 4.53 A 8.25 A
10–7 + 10–4 4.28 ± 2.81 9.02 sA –4.89 ± 4.35 NDAd 9.18 NDAd
2.5 × 10–7 + 10–6 56.81 ± 10.68 0.29 sS 31.44 ± 11.83 S 32.18* S
10–6 + 10–6 39.71 ± 4.56 1.25 mA –8.81 ± 8.74 A 48.52 A
10–6 + 5 × 10–5 17.50 ± 4.17 3.99 sA –35.92 ± 8.55 A 53.42*** A
10–6 + 10–4 2.93 ± 3.14 83.33 sA –51.42 ± 8.29 A 54.35*** A
10–5 + 10–6 41.10 ± 5.22 2.42 A –37.92 ± 12.05 A 79.02*** A
10–5 + 5 × 10–5 16.85 ± 5.28 8.52 sA –67.07 ± 12.07 A 83.92*** A
10–5 + 10–4 7.92 ± 2.49 25.54 sA –76.93 ± 11.28 A 84.85*** A
Abbreviations: A, antagonism; NDAd, not different from additive; S, synergism. 
aMolar concentration (BaP is shown first); bFraction affected (fa) is the background-corrected observed mutation 
frequency for the combinations/106 viable cells ± SEM; cCI = (D1/Dx1) + (D2/Dx2); D1, D2 are the concentrations used in the 
mixture, and Dx1, Dx2 are the concentrations of individial chemicals required to achieve the mixture effect; dSynergism 
and antagonism are subdivided into nearly additive (NAd, 0.9–1.1), moderate synergism/antagonism (mS, 0.7–0.90/mA,1.1–
1.45), synergism/antagonism (S, 0.3–0.7/ A, 1.45–3.3), and strong synergism/antagonism (sS, < 0.1–0.3/ sA, 3.3 to > 10); 
eIF = G1G2 – G1 – G2 + C ± SEM. A negative IF = antagonism (A), positive IF = synergism (S), 0 = not different from additive 
(NDAd); fIA = MF1 + MF2 – [(MF1MF2)/106]; MF1 and MF2 = individual MF, MF1MF2 = product of individual MFs; gMechanism 
deduced by comparison of the predicted MF with the actual MF (fraction affected). Observed and predicted MF response 
compared using a t-test with Bonferroni multiple comparisons test (*p ≤ 0.05; ***p ≤ 0.001). Variance surrounding the 
expected MF was assumed to equal the variance for the observed data (Abendroth et al. 2011).
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CYP1A activity, was measured in cells treated 
with BaP or PhIP alone or with mixtures of 
BaP and PhIP. The results showed induction 
of EROD activity at concentrations ≥ 10–7 M 
BaP (Figure 2A), whereas induction was only 
observed with 10–8 M PhIP (Figure 2B). For 
the selected combinations, the results showed 
induction of EROD activity for mixtures of 
10–7 M BaP and 10–6 M PhIP, 2.5 × 10–7 M 
BaP and 10–6 M PhIP, and 10–6 M BaP and 
10–6 M PhIP, with no induction observed 
for other combinations tested (Figure 2C). 
EROD activity for mixtures was signifi­
cantly correlated with TK MF (p = < 0.0001, 
R = 0.78; Figure 2D).
It should be noted that EROD activity 
cannot be measured > 10–5 M BaP because 
this is above the Km for CYP1A1 where BaP 
outcompetes 7­ER for CYP (Crofts et al. 1997).
CYP1A1  mRNA expression levels . 
qRT­PCR performed on cells treated with 
mixtures of BaP and PhIP showed significant 
increases of CYP1A1 mRNA (compared with 
control) for mixtures with concentrations 
≥ 10–7 M BaP and 10–6 M PhIP. However, at 
each BaP concentration ≥ 10–7 M, the increase 
in CYP1A1 expression diminished as the PhIP 
concentration increased (e.g., for mixtures 
of 10–5 M BaP plus PhIP at concentrations 
of 10–6, 10–5, and 10–4 M) (Figure 2E). 
The CYP1A1 mRNA levels were signifi­
cantly correlated with the TK MF profile 
(p = < 0.0001, R = 0.80; Figure 2F).
Cell cycle. To determine whether altera­
tions in cell cycle played a role in the altered 
MF response that was observed after exposure 
to combinations of BaP and PhIP, cell cycle 
status was measured following a 24­hr treat­
ment with selected combinations and after 
24­hr and 48­hr recovery phases.
We observed a significant decrease in the 
number of cells in S phase after 24 hr for the 
two highest dose combinations [10–5 M BaP 
combined with either 5 × 10–5 M (p ≤ 0.05) 
or 10–4 M PhIP (p ≤ 0.01); Table 3]. There 
was also a corresponding significant increase 
in the sub­G1 population, which was signifi­
cant for all combinations except for 10–9 M 
BaP mixed with 10–9 M PhIP (Table 3), a 
finding that is suggestive of apoptosis.
Following a 24­hr recovery period, 
significant increases in the number of cells in 
sub­G1 were observed for combinations of 
≥ 10–7 M BaP with 10–6 M PhIP, suggestive 
of apoptosis, and a significant increase in the 
number of cells in G2/M phase was observed 
for mixtures of 10–6 M BaP with 5 × 10–5 M 
PhIP and of 10–5 M BaP with either 5 × 10–5 
or 10–4 M PhIP (Figure 3C,D and Table 3). 
Accumulation of cells in G2/M phase occurred 
for mixtures where antagonistic effects were 
observed and may reflect a block in the cell 
cycle to allow DNA repair.
Following a 48­hr recovery period, a 
significant accumulation of cells in G1 phase 
was observed for the combinations of 10–6 M 
BaP with 5 × 10–5 M PhIP and 10–5 M BaP 
with 10–4 M PhIP (Table 3). This pattern of 
cell­cycle phase accumulation is indicative of 
Figure 2. Effects of BaP and PhIP mixtures on CYP1A activity and CYP1A1 expression. For all mixtures, the concentration of BaP is stated first. Ethoxyresorufin-O-
deethylase (EROD) activity was determined following a 24-hr treatment with (A) BaP, (B) PhIP, or (C) mixtures of BaP and PhIP. (D) CYP1A1 mRNA levels (Q-PCR, 
normalized to GAPDH) following a 24-hr treatment with mixtures of BaP and PhIP. Correlation of mixture TK MF with (E) mixture EROD or (F) mixture CYP1A1 
mRNA levels. Data are means ± SEM, n = 3. Significance compared with the DMSO control (one-way ANOVA with Dunnett’s post-test; *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001).
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a population of synchronized cells moving 
through the cycle after arrest release (Creton 
et al. 2005; Zhu et al. 2000).
Expression of mismatch repair proteins 
MSH2 and MSH6. PhIP has been linked 
to induction of G2 arrest and to an increase 
in levels of MSH6/GTBP (Creton et al. 
2005). To determine whether the reduced 
MF observed at some concentrations of the 
mixtures was associated with increased DNA 
repair, levels of mismatch repair proteins 
MSH2 and MSH6 (hMutSa complex) 
were measured.
Following treatment with selected mixtures 
of BaP and PhIP (10–7 M or 10–5 M BaP 
with either 10–6 M, 5 × 10–5 M, or 10–4 M 
PhIP), MSH6 protein levels were apparently 
greater for mixtures containing 10–5 M BaP 
than for combinations containing 10–7 M BaP 
(although no combinations tested were statisti­
cally significantly different from the control) 
where antagonistic induction of TK MF was 
observed (e.g., 10–5 M BaP with 10–6 M PhIP) 
(Figure 4A,C). No change in the level of 
MSH2 was observed (Figure 4B,C).
Because PhIP has been linked with induc­
tion of G2 arrest and mismatch repair (Creton 
et al. 2005; Duc and Leong­Morgenthaler 
2004), levels of MSH6 were measured after 
treating cells with PhIP for 24 hr. A dose­
dependent increase in MSH6 protein was 
observed; however, this increase was only 
significant at a PhIP concentration of 10–4 M 
(Figure 4D), suggesting that PhIP may be 
responsible for induction of MSH6 protein by 
the mixtures.
Discussion
Eating cooked red meat is strongly correlated 
with diet­associated cancers, and cooking 
meat leads to the formation of chemical 
carcinogens such as BaP and PhIP (Sinha 
et al. 2005). Many studies have investigated 
DNA damage caused by individual chemicals, 
but few have examined the consequences of 
exposure to chemical mixtures. The present 
study aimed to examine mixtures of the food­
borne genotoxic carcinogens BaP and PhIP 
at doses that are relevant to human exposure.
The results from the TK mutation assay 
showed that BaP induced a statistically 
significant increase in MF at concentra­
tions > 10–7 M, whereas PhIP significantly 
increased MF at concentrations ≥ 5 × 10–5 
M. In V79 Chinese hamster cells, MF at 
the HPRT locus was more pronounced in 
response to PhIP (Yadollahi­Farsani et al. 
1996) than was TK MF in MCL­5 cells 
exposed to the same PhIP cocentrations in 
the present study. However, V79 cells express 
a nonfunctional p53 protein (Chaung et al. 
1997) and are more susceptible to mutation 
than MCL­5 cells, which have a functional 
p53 response (Guest and Parry 1999).
It is noteworthy that 10–7 M BaP and 
10–6 M PhIP did not increase MF with indi­
vidual exposure (Table 1), whereas in combi­
nation, they induced a significant mutation 
response that was synergistic based on CI, 
IF, and IA analyses (Table 2). A recent report 
using the micronucleus assay showed that 
binary mixtures of chemicals with dissimilar 
actions at their “no observed genotoxic effect 
levels” induced a significant increase in micro­
nuclei, supporting our findings (Johnson 
et al. 2012). In contrast, the combined effect 
for the combination of 10–5 M BaP and 
10–4 M PhIP was significantly and substan­
tially lower than the effect predicted based on 
an expectation of additive effects.
Both compounds require metabolic acti­
vation by CYP1A1 family enzymes (IARC 
2010; Zhao et al. 1994). EROD activity 
was significantly correlated with the trend 
for MF, suggesting that CYP1A is required 
for mutation. In support of this hypoth­
esis, CYP1A1 mRNA levels were strongly 
Table 3. Effects of selected combinations of BaP and PhIP on cell cycle distribution assessed by flow cytometry.
BaP + PhIP (M)
24 hr 24 hr post 48 hr post
Sub G1 G1 S G2/M Sub G1 G1 S G2/M Sub G1 G1 S G2/M 
DMSO 4.99 ± 1.30 34.30 ± 2.05 21.93 ± 1.70 24.30 ± 1.31 0.97 ± 0.36 36.20 ± 0.83 30.97 ± 1.68 21.80 ± 0.81 0.11 ± 0.24 43.97 ± 0.91 21.23 ± 0.52 23.00 ± 0.70
10–9 + 10–9 4.92 ± 0.77 34.77 ± 1.57 19.47 ± 0.59 26.17 ± 0.97 1.27 ± 0.20 35.10 ± 0.46 31.47 ± 1.91 22.90 ± 1.87 1.08 ± 0.39 42.93 ± 1.02 19.77 ± 1.29 22.37 ± 1.23
10–7 + 10–6 4.72 ± 0.51 35.73 ± 1.34 22.87 ± 0.98 23.80 ± 0.72 2.38 ± 0.07* 37.07 ± 0.90  28.60 ± 2.7 24.97 ± 1.12 1.30 ± 0.52 40.97 ± 0.94 20.80 ± 0.45 23.83 ± 0.99
2.5 × 10–7 + 10–6 6.65 ± 1.12 33.93 ± 1.77 22.80 ± 1.27 23.00 ± 1.18 2.99 ± 0.50*** 36.30 ± 0.90 26.97 ± 1.36 27.07 ± 1.30 1.46 ± 0.24 40.00 ± 2.48 20.77 ± 2.00 24.37 ± 0.43
10–6 + 5 × 10–5 7.34 ± 1.03 34.30 ± 1.05 18.07 ± 1.19 25.77 ± 0.10 2.45 ± 0.27* 33.50 ± 0.62 28.80 ± 1.03 28.40 ± 0.40* 1.59 ± 0.90 36.60 ± 2.36* 22.27 ± 1.00 25.37 ± 0.88
10–5 + 10–6 7.41 ± 1.08 33.90 ± 0.67 22.97 ± 1.74 22.57 ± 0.55 3.84 ± 0.16*** 32.43 ± 0.58 31.27 ± 2.07 26.70 ± 2.31 6.08 ± 1.31 37.93 ± 1.61 21.57 ± 4.53 24.23 ± 1.51
10–5 + 5 × 10–5 8.74 ± 1.04 34.47 ± 0.73 15.23 ± 0.55* 25.93 ± 0.53 3.67 ± 0.25*** 33.60 ± 1.06 28.80 ± 2.45 29.73 ± 1.79** 2.10 ± 0.17 40.23 ± 2.47 22.57 ± 1.18 24.33 ± 0.07
10–5 + 10–4 13.00 ± 2.40** 39.73 ± 2.31 14.07 ± 1.24** 22.13 ± 0.44 3.38 ± 0.29*** 32.83 ± 1.07 29.57 ± 1.04 30.73 ± 0.77*** 1.89 ± 1.08 34.77 ± 1.56** 26.03 ± 0.49 23.93 ± 1.77
Data are presented as the percentage of cells in each phase of the cell cycle ± SEM, n = 3. MCL-5 cells were treated for 24 hr, as indicated, then harvested or left in fresh media for a further 24 hr (24 hr post) or 48 
hr (48 hr post) after treatment. Dimethylsulfoxide (DMSO) was used as a negative control. Significance compared with the negative control was calculated using one-way ANOVA with Dunnett’s post-test (*p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001).
Figure 3. Effects of mixtures of BaP and PhIP on cell cycle. Percentage of cells in each phase of the cell 
cycle after a 24-hr treatment with (A) dimethylsulfoxide (DMSO; negative control) or with (B, C, D) selected 
combinations of BaP and PhIP followed by a 24-hr recovery period. Assessed by flow cytometry.
PE, propidium iodide staining.
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correlated with TK MF. The increase in 
expression and activity of CYP1A1 was 
expected because BaP induces CYP1A1 
expression via the aryl hydrocarbon receptor 
(AhR) (Nebert et al. 1993). The correlation 
of CYP1A1 expression and activity with the 
observed TK MF suggests that increased acti­
vation of the chemicals may represent one 
reason for the observed synergism. The Kms 
of BaP and PhIP for human CYP1A1 are 
8.8 μM and 5.1 μM, respectively, and the Km 
of PhIP for human CYP1A2 is 79 μM (Crofts 
et al. 1997; Schwarz et al. 2001). Thus, for 
mixtures where MF synergy was observed, the 
BaP/PhIP concentrations were below the Km 
of CYP1A1 and CYP1A2, and the enzymes 
were working with maximum efficiency. 
Unexpectedly, the induction of CYP1A1 
mRNA and EROD decreased as the concen­
tration of PhIP in the mixture increased, in 
line with the lower TK MF observed for these 
mixture concentrations. A possible explana­
tion for the lack of induction of CYP1A1 with 
increasing PhIP in the mixture is that PhIP is 
estrogenic and can mediate gene transcription 
via the estrogen receptor (ER) (Lauber et al. 
2004). Aryl hydrocarbon receptor nuclear 
translator (ARNT) is recruited to estrogen­
responsive promoters in the presence of 
estradiol (Swedenborg and Pongratz 2010); 
thus, PhIP may be recruiting ARNT to ER, 
reducing its availability for AhR and CYP1A1 
transcription and therefore for CYP1A 
activity. Although elevation of CYP1A mRNA 
was observed for high­concentration mixtures 
(PhIP with 10–5 M BaP), the observed 
increases in TK MF were less than additive. At 
these high concentrations, access to metabolic 
enzymes becomes competitive (based on the 
Kms for BaP and PhIP), thus limiting the 
formation of DNA­damaging metabolites and 
resulting in antagonism of MF. 
Another possible explanation reflects 
the cell cycle status of cells. Analysis of the 
cell cycle 24 hr after treatment with selected 
combinations of BaP and PhIP revealed 
significant accumulation of cells in sub­G1 
and a block at G2/M, which was dose­
dependent with increasing concentrations of 
PhIP. Treatment with mixtures of 10–6 M 
BaP and 5 × 10–5 M PhIP, or 10–5 M BaP 
and either 5 × 10–5 M or 10–4 M PhIP, led 
to a significant accumulation of cells in 
G2/M and an antagonistic effect on TK MF, 
suggesting that G2/M–phase arrest may play 
a role in the observed low MF. Although a 
significant induction of CYP1A1 expression 
was observed for these combinations, sugges­
tive of increased activation by the chemicals 
and therefore of increased DNA damage, 
activation of G2/M–phase arrest may allow 
damage repair, thereby reducing MF towards 
baseline levels. Indeed, this G2/M block was 
not observed 48 hr after treatment, suggesting 
that the damage had been repaired. The 
temporal dependency of accumulation of 
cells at different stages of the cell cycle could 
reflect release of cells from the initial S­phase 
block, synchronizing this cell population.
Arrest at G2/M has been reported for 
these chemicals individually; BaP (10–5 M) 
has been shown to induce G2/M phase arrest 
following a 48­hr treatment (Drukteinis et al. 
2005), and activation of the G2/M check­
point has been reported 24 hr after PhIP 
treatment (Duc and Leong­Morgenthaler 
2004). Moreover, a recent study showed that 
complex mixtures of PAHs activated check­
point kinase 1 (Chk1) (Jarvis et al. 2013), 
which mediates G2/M phase arrest. G2/M 
arrest has been linked to mismatch repair for 
certain types of DNA damage (Aquilina et al. 
1999; Duc and Leong­Morgenthaler 2004; 
Hawn et al. 1995), and the involvement of 
GTBP/MSH6 in PhIP­induced mutagen­
esis has previously been reported, with levels 
of these proteins elevated following PhIP 
exposure (Creton et al. 2005). In the present 
study, levels of MSH6 protein appeared to 
increase more after a 24­hr treatment with 
mixtures containing 10–5 M BaP than for 
those containing 10–7 M BaP. MSH6 forms 
the MutSα complex with MSH2; this 
heterodimer binds bulky adducts at the C8 
position of guanine produced by amino­
fluorene (AF) and 2­acetyl­4­aminofluorene 
(AAF) (Li et al. 1996), and it is believed to 
be involved in repair of this type of DNA 
damage. Because PhIP generates bulky 
Figure 4. Effects of mixtures of BaP and PhIP, or PhIP alone, on mismatch-repair proteins. Effects of a 24-hr treatment with selected concentrations of mixtures of 
BaP (stated first) and PhIP on the expression of (A) MSH6 or (B) MSH2. (C) Representative immunoblots showing the abundance of MSH6 and MSH2 proteins. (D) 
Effects of a 24-hr treatment with selected concentrations of PhIP on MSH6 protein expression. The intensity of each protein in DMSO-treated cells was used as 
a reference after correcting for loading (β-actin). Data are presented as the mean ± SEM, n = 3. Significance compared with the DMSO control calculated using 
one-way ANOVA with Dunnett’s post-test (*p ≤ 0.05).
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adducts at the C8 position of guanine, it is 
hypothesised that mismatch­repair proteins 
are also involved in recognizing dG­C8­PhIP 
adducts (Duc and Leong­Morgenthaler 2004; 
Glaab et al. 2000). Induction of MSH6 
protein supports the induction of cell cycle 
arrest to repair DNA damage from high­dose 
mixtures. Interestingly, involvement of DNA 
repair in nonmonotonic dose responses has 
been reported in relation to the HPRT assay 
(Jenkins et al. 2010) and more recently in 
reference to low­dose “no observed genotoxic 
effect levels” (Thomas et al. 2013).
Conclusions
Co­exposure to BaP and PhIP produced 
mutation responses that differed consider­
ably from those expected based on the IA 
model of additivity. Combining the demon­
strated nonmutagenic dose of 10–7 M BaP 
with the similarly nonmutagenic dose of 
10–6 M PhIP resulted in a significant increase 
in TK MF. This effect may be mediated by 
CYP1A enzymes because EROD activity and 
CYP1A1 mRNA were correlated with MF 
(Figure 2). However, it should be noted that 
the majority of the tested mixtures led to 
antagonistic effects. The less­than­additive TK 
MF observed for high­dose mixtures implies 
that such combinations are less mutagenic. 
Our data suggest the involvement of DNA 
repair, mediated via G2/M­phase arrest, for 
mixtures containing 10–5 M BaP. We hypoth­
esize that in BaP–PhIP mixtures, BaP is the 
dominant mutagen and makes the greatest 
contribution to the mutation response. This 
hypothesis is supported by the increase in 
CYP1A1 mRNA levels, which is likely to be 
BaP­driven because PhIP is a weak inducer of 
CYP1A1 (Thomas et al. 2006).
The increase in MF for low­ concentration 
mixtures may be of significance when 
considering the genotoxic potential of food. 
These concentrations are relevant to human 
exposure, and as such, our results may have 
implications for risk assessment because when 
mixtures are analyzed on the basis of their 
components, a general assumption is made 
that interaction effects at low dose levels either 
do not occur or are small enough to be insig­
nificant to the risk estimate (U.S. EPA 2000). 
Our data show possible non­monotonic dose 
responses, and future work investigating DNA 
adduct formation would help clarify this issue.
When interpreting our observations, the 
limitations of current in vitro mutation assays 
must be appreciated, and the contribution 
of metabolism to these processes is a promi­
nent consideration. Although the MCL­5 cell 
line used in the present study is competent 
for phase I metabolism of BaP and PhIP, it 
has limited ability to perform the totality of 
metabolic reactions that are available in intact 
mammals. All such in vitro mutagenicity 
models have deficient phase II metabolism, 
and the majority require added Phase I capa­
bility (S9), which limits detoxication, thereby 
biasing toward a positive mutation response. 
In this respect, our cell­based system is similar 
to other in vitro mutation assays, and all are 
likely to overrepresent mutation potential. 
Thus, detection of MF in in vitro mamma­
lian cell systems should be viewed as indicative 
of mutagenic potential, and further investi­
gation of the mixture concentrations tested 
herein is required in vivo to fully assess the 
impact of these data on human health and for 
risk assessment.
Editor’s Note: Equation 4 in the Advance 
Publication was incorrect. The correct equation 
is included in this article.
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